SHANGHAI, China I April 30, 2025 I Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results ...

CAMBRIDGE, MA, USA I April 30, 2025 I Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has ...

PLAINSBORO, NJ, USA I April 30, 2025 I Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE ...

Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop ...

PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory ...

SOUTH SAN FRANCISCO, CA, USA I April 30, 2025 I Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus ...